211 related articles for article (PubMed ID: 23076343)
1. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the binding of cis/trans-[MCl4(1H-indazole)(NO)](-) (M = Ru, Os) complexes to human serum albumin.
Dömötör O; Rathgeb A; Kuhn PS; Popović-Bijelić A; Bačić G; Enyedy EA; Arion VB
J Inorg Biochem; 2016 Jun; 159():37-44. PubMed ID: 26908285
[TBL] [Abstract][Full Text] [Related]
3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
4. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
5. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
[TBL] [Abstract][Full Text] [Related]
6. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
Bijelic A; Theiner S; Keppler BK; Rompel A
J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
[TBL] [Abstract][Full Text] [Related]
7. Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis(imidazol)ruthenate(III)].
Trynda-Lemiesz L; Keppler BK; Kozłowski H
J Inorg Biochem; 1999 Mar; 73(3):123-8. PubMed ID: 10331241
[TBL] [Abstract][Full Text] [Related]
8. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.
Cetinbas N; Webb MI; Dubland JA; Walsby CJ
J Biol Inorg Chem; 2010 Feb; 15(2):131-45. PubMed ID: 19707803
[TBL] [Abstract][Full Text] [Related]
9. Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III).
Trynda-Lemiesz L; Karaczyn A; Keppler BK; Kozłowski H
J Inorg Biochem; 2000 Mar; 78(4):341-6. PubMed ID: 10857915
[TBL] [Abstract][Full Text] [Related]
10. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
[TBL] [Abstract][Full Text] [Related]
11. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
[TBL] [Abstract][Full Text] [Related]
12. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
[TBL] [Abstract][Full Text] [Related]
13. LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
Bytzek AK; Boeck K; Hermann G; Hann S; Keppler BK; Hartinger CG; Koellensperger G
Metallomics; 2011 Oct; 3(10):1049-55. PubMed ID: 21935553
[TBL] [Abstract][Full Text] [Related]
14. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
Bytzek AK; Koellensperger G; Keppler BK; G Hartinger C
J Inorg Biochem; 2016 Jul; 160():250-5. PubMed ID: 26993078
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
[TBL] [Abstract][Full Text] [Related]
17. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
18. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
[TBL] [Abstract][Full Text] [Related]
19. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
[TBL] [Abstract][Full Text] [Related]
20. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
Kratz F; Hartmann M; Keppler B; Messori L
J Biol Chem; 1994 Jan; 269(4):2581-8. PubMed ID: 8300587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]